Several Research Avenues Are Available for Improving Respons

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

Related Keywords

China , United States , Chinese , Eli Lilly , Cobo Dols , Merck Serono , Roche Genentech , Tonys Mok , Bristol Myers Squibb , Pfizer , Chinese University Of Hong Kong , Vertex Pharmaceuticals , Sanomics Ltd , International Lung Cancer Congress , Novartis , Astrazeneca , Boehringer Ingelheim , Chinese Lung Cancer Research Foundation Ltd , Clinical Oncology , Chinese University , Hong Kong , Annual International Lung Cancer , Merck Sharp , Clovis Oncology , International Association , Lung Cancer , Annual International Lung Cancer Congress , Huntington Beach , Treating Field , Garcia Campelo , D ,